| 摘要 |
<p>PROBLEM TO BE SOLVED: To provide a method for monitoring or determining patient's risks of diabetic nephropathy or related disorders and improving diabetes management.SOLUTION: A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include N-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and Ncarboxymethyllysine (CML).</p> |
